Compare · CNTG vs HUM
CNTG vs HUM
Side-by-side comparison of Centogene N.V. (CNTG) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTG and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $49.64B, about 532.1x CNTG ($93.3M).
- HUM has hit the wire 13 times in the past 4 weeks while CNTG has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 1 for CNTG).
- Company
- Centogene N.V.
- Humana Inc.
- Price
- $0.56+86.47%
- $215.14+0.15%
- Market cap
- $93.3M
- $49.64B
- 1M return
- -
- +23.51%
- 1Y return
- -
- -18.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 13
- Recent ratings
- 1
- 25
Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CNTG
- CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
- CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
- CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
- SEC Form 6-K filed by Centogene N.V.
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
- Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.
Latest HUM
- SEC Form 3 filed by new insider Field Robert Stuart
- Humana Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CenterWell Introduces the Fulfillment Index, a New Measure of What It Means to Age Well
- SEC Form S-8 filed by Humana Inc.
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- On the Line for Lung Health: Telephone Training Helps COPD Patients Perfect Inhaler Use
- Tuesday Health Expands National Footprint With Humana Partnership to Advance Value-Based Palliative Care
- Humana Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Humana Elects Robert S. Field to Board of Directors
- Humana Goes Live with b.well to Deliver on Health Data Interoperability Commitments